What is OBIO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.36B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for OBIO?

P/E (TTM) is n/a and 52-week range is $2.66 to $6.50 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s OBIO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for OBIO?

The company profile lists revenue (TTM) near $30M, net income (TTM) near $-5.53B, EPS (TTM) near $-1.00 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Orchestra Biomed Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New Hope, Pennsylvania, US, 59.9M shares outstanding, ISIN US68572M1062 when available from company profile and filing metadata.

Orchestra Biomed Holdings Inc

$OBIO

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

$5.95

+3.84%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania and currently employs 86 full-time employees. The company went IPO on 2020-08-04. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The firm develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

Employees

Website

www.orchestrabiomed.com

IPO

2020-08-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)